S
Spero Therapeutics D
D
SPRO
3.00500
USD
0.07
(2.39%)
مغلق
حجم التداول
58,683
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
168,011,476
الأخبار المقالات
العنوان: Spero Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.